This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
LeMaitre Vascular (LMAT) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of +5.26% and +2.53%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
PAHC vs. LMAT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PAHC vs. LMAT: Which Stock Is the Better Value Option?
LeMaitre Vascular (LMAT) Lags Q1 Earnings Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of -4% and 3.59%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
BD Stock Down Despite Monitoring Platform Launch to Boost Patient Care
by Zacks Equity Research
BDX's AI-based advanced hemodynamic monitoring platform is likely to aid clinicians to address blood flow instability and pressure in critical situations and improve patient outcomes.
FitLife Brands (FTLF) Surges 13.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
FitLife Brands (FTLF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
BAX Stock Declines Despite Latest Product Launch Boosting Patient Care
by Zacks Equity Research
Baxter aims to promote enhanced patient care through the evolution of its latest product, which enables direct accessibility in the operating room.
LeMaitre (LMAT) Soars 7.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
LeMaitre (LMAT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
4 Low-Beta Healthcare Stocks to Beat Trump's Tariff Blues
by Ritujay Ghosh
Healthcare stocks like GLID, COR, FMS and LMAT are a safe bet during times of market volatility.
3 Reasons Growth Investors Will Love LeMaitre (LMAT)
by Zacks Equity Research
LeMaitre (LMAT) could produce exceptional returns because of its solid growth attributes.
Down -15.37% in 4 Weeks, Here's Why LeMaitre (LMAT) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for LeMaitre (LMAT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
3 Best Earnings Growth Stocks to Buy in March: CAKE, LMAT, HURN
by Tirthankar Chakraborty
The Cheesecake Factory, LeMaitre Vascular and Huron Consulting Group are currently displaying superb earnings growth.
Ensign Group Expands Healthcare Portfolio With Key Acquisitions
by Zacks Equity Research
ENSG acquires skilled nursing and senior living facilities across four states, expanding its U.S. footprint and bringing higher revenues for its Skilled Services segment.
Best Momentum Stocks to Buy for March 4th
by Zacks Equity Research
OPCH and LMAT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 4, 2025.
New Strong Buy Stocks for March 4th
by Zacks Equity Research
OPCH, LMAT, C, FFIN and IBCP have been added to the Zacks Rank #1 (Strong Buy) List on March 4, 2025.
LeMaitre (LMAT) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
LeMaitre (LMAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
LeMaitre Vascular (LMAT) Meets Q4 Earnings Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of 0% and 0.76%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics (HAE) Q3 Earnings Meet Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of 0% and 1.30%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
4 Healthcare Stocks Rising More Than 50% in 2024 With Room to Grow
by Debasmita Chatterjee
Medical stocks are expected to reap the benefits of affordable health insurance plans, rising surgeries and widespread adoption of telehealth services in the days ahead. However, inflation and supply-chain woes may act as spoilsport.
BDX Stock Down Despite New Expansion to Boost Fingertip Blood Testing
by Zacks Equity Research
The blood testing process integrating BD's MiniDraw System with Babson's BetterWay technologies is likely to lower common barriers to testing and improve patient outcomes.
STXS Stock Up Post NMPA Nod for Cardiovascular Care With Magbot
by Zacks Equity Research
Stereotaxis' latest regulatory approval in China is likely to offer a minimally-invasive treatment solution for complex arrhythmia patients and improve global cardiovascular care.
RMD vs. LMAT: Which Stock Is the Better Value Option?
by Zacks Equity Research
RMD vs. LMAT: Which Stock Is the Better Value Option?
Community Health to Sell Florida Hospital to AdventHealth for $265M
by Zacks Equity Research
CYH enters an agreement to sell ShorePoint Health System assets in Florida for $265 million, advancing its strategy to shed non-core facilities and enhance focus on growth areas.
LeMaitre Vascular (LMAT) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of 11.36% and 2.17%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
BAX or LMAT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BAX vs. LMAT: Which Stock Is the Better Value Option?
BAX vs. LMAT: Which Stock Is the Better Value Option?
by Zacks Equity Research
BAX vs. LMAT: Which Stock Is the Better Value Option?